BioVie’s bezisterim improves Parkinson’s symptoms in Phase 2 trial subgroup with higher inflammation
BIVI•BioVie said patients with early Parkinson’s disease and higher baseline inflammation showed significant motor and non-motor symptom improvements with bezisterim versus placebo in a 57-patient Phase 2 trial. The company plans to present additional findings at AD/PD2027 on March 20, 2027.
1. Trial findings
BioVie said its randomized, placebo-controlled Phase 2 SUNRISE-PD trial evaluated 57 patients with early Parkinson’s disease over 12 weeks. Patients with higher baseline inflammation showed the strongest response, with significant improvements in motor and non-motor symptoms compared with placebo. Overall, treated patients were more likely to achieve meaningful clinical improvement and less likely to worsen than placebo recipients.
2. Upcoming presentation
BioVie plans to present additional bezisterim findings from the trial at AD/PD2027 in Barcelona on March 20, 2027.
Related News
Nuwellis secures exclusive US distribution rights for Zorro-Flow pediatric urine collection system
Conexeu Sciences launches human collagen initiative for regenerative aesthetics as GLP-1 drives demand for tissue restoration
